Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance

Fig. 6

EGFR blockade synergizes with standard chemotherapy to inhibit the migratory potential of osteosarcoma cells. a For scratch assays, HOS cells were treated with standard chemotherapy (MTX, doxorubicin) without and with 1 μM gefitinib and wound healing was followed at two positions of the wound up to 48 h as indicated. Means and S.D. of two experiments are shown. b Transwell migration assays were performed with HOS, IOR-MOS and OS-10 cells for 48 h at subtoxic concentrations of doxorubicin without and with 1 μM gefitinib. Clonogenic growth in the lower chamber was analysed as under Fig. 3b. Selected wells containing crystal violet-stained osteosarcoma cell clones are opposed to quantification of experiments performed in triplicate. One-way ANOVA with Bonferroni’s post hoc test (a) and Students t-test (b); * p < 0.05; ** p < 0.01; *** p < 0.001

Back to article page